Cubist Changes Internet Press Release Policy After FDA Letter On Daptomycin
Executive Summary
Cubist Pharmaceuticals will purge press releases from its website after six months in response to a Nov. 22 letter from FDA maintaining that Cubist's press releases available on the Internet amount to pre-approval promotion of Cidecin (daptomycin).